Quantcast

Latest CD4 Stories

2011-12-01 18:47:55

Results of clinical trial in Uganda suggest better way to spend money fighting disease in rural Africa A cheaper laboratory test that helps guide anti-retroviral drug treatment for people with HIV/AIDS may be just as effective as a more sophisticated test, a group of international researchers has found — a discovery that could be particularly important in rural Africa. While the findings by researchers in the United States, Canada and Uganda must still be confirmed through...

2011-10-27 22:10:50

Caltech biologists create neutralizing antibody that shows increased potency Using highly potent antibodies isolated from HIV-positive people, researchers have recently begun to identify ways to broadly neutralize the many possible subtypes of HIV. Now, a team led by biologists at the California Institute of Technology (Caltech) has built upon one of these naturally occurring antibodies to create a stronger version they believe is a better candidate for clinical applications. Current...

2011-09-27 12:02:51

One of the key decisions faced by people living with HIV, and by their health-care providers, is when to start treatment. Some recent studies have found that starting highly active antiretroviral therapy earlier is better. Now a new study led by researchers at the University of North Carolina at Chapel Hill finds that there may be a limit to how early the therapy, known as HAART, should start. The new results could help determine where the starting line for antiretroviral therapy should...

2011-08-20 07:00:00

SeraCare announced the addition of Cryo-M Human Monocytes and Cryo-T4 Human CD4+ T-Cells to its AccuCell® Peripheral Blood Mononuclear Cell (PBMC) portfolio. Milford, MA (PRWEB) August 20, 2011 SeraCare Life Sciences, a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announced it has expanded its cellular product line with the addition of Cryo-M Human Monocytes and Cryo-T4...

2011-07-20 12:19:43

In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment. Some patients never return for the results of their initial CD4 count (a prognostic and treatment eligibility biomarker); some disappear between having their initial CD4 count taken and becoming eligible for HIV treatment; and others with CD4 counts that indicate that they are eligible for...

2011-07-11 08:00:00

WORCESTER, Mass. and TORONTO, July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology. Antigen Express, Inc., the Company's wholly-owned subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer. AE37, an Ii-Key HER-2 hybrid, is currently the subject of a...

2011-06-15 21:17:50

Specific types of "helper" T cells that are crucial to maintaining functioning immune systems contain an enzyme called PDI (protein disulfide isomerase). This enzyme affects how proteins fold into specific shapes, which in turn influences how the T cells behave. PDI also plays a role in HIV infection by helping to change the shape of the surface envelope protein of the virus, enabling the virus to interact optimally with receptors on the T cells, such as the CD4 molecule. Though it is known...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related